IPO SnapShot

ERIS LIFESCIENCES LTD.

IPODATE
Jun 16, 2017 TO Jun 20, 2017
LISTINGDATE
6/29/2017 12:00:00 AM
APPLY NOW
FACEVALUE
₹ 1

per share

ISSUESIZE
₹ 961.71 Cr
PRICEBAND
₹ 600 - ₹ 603

per share

MARKETLOT
24

shares

OBJECTIVE

The objects of the Offer are to achieve the benefits of listing the Equity Shares on NSE and for the sale of Equity Shares by the Selling Shareholders. Further, our Company expects that listing of the Equity Shares will enhance its visibility and brand image and provide liquidity to its existing Shareholders. Our Company will not receive any proceeds of the Offer and all the proceeds of the Offer will go to the Selling Shareholders in the proportion of the Equity Shares offered by them.

DON'T HAVE A DEMAT ACCOUNT

OPENDEMAT ACCOUNTAND START YOURINVESTMENTJOURNEY WITH US

OPEN AN ACCOUNT (You will receive a call & SMS from our end)
BUSINESS DESCRIPTION

We develop, manufacture and commercialize branded pharmaceutical products in select therapeutic areas withinthe chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology;and anti-infectives. Our focus has been on developing products in the chronic and acute category which are linkedto lifestyle related disorders. The chronic category of the IPM...

ADDRESS

Address: Shivarth Ambit
Plot No. 142/2
Ramdas Road
Off S B R
Near Swati Bungalows
Bodakdev
City: Ahmedabad,
State: Gujarat
Pincode: 380054
Phone: 079 30451000 / 1001
Email: eris@erislifesciences.com
Website: www.eris.co.in

LISTED AT

BSE, NSE

LEAD MANAGER

Axis Capital Ltd.
Citigroup Global Markets India Pvt Ltd.
Credit Suisse Securities (India) Pvt Ltd.

PROMOTERS

Amit Indubhushan Bakshi
Himanshu Jayantbhai Shah
Inderjeet Singh Negi
Kaushal Kamlesh Shah
Rajendrakumar Rambhai Patel

PROMOTER'S HOLDING

Total Share Capital

Offered to Public

-

Promoter's Holding (Pre-Issue)

Promoter's Holding (Post-Issue)

REGISTRAR

Link Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.